MAIN ARTICLE
From a blood sample to a family decision
A medical appointment about forgetfulness can become the beginning of a lengthy journey. Clinicians assess thinking and memory, look for potentially treatable causes and sometimes refer the patient to a specialist. Amyloid PET scans and tests of cerebrospinal fluid can reveal changes associated with Alzheimer’s, but expense, invasive procedures and long journeys to specialist centres place them beyond easy reach for some families.
Blood-based biomarkers offer a less invasive route. In May 2025, the FDA cleared Fujirebio’s Lumipulse test, which measures the ratio of pTau217 to amyloid beta 1-42. In August 2026, it also cleared Roche’s Elecsys pTau217 assay. These tests help clinicians assess the likelihood of amyloid pathology in the brain and decide whether further evaluation is warranted. The advance is a diagnostic aid, not a declaration of certainty.
The qualification matters. A test result alone cannot establish a definitive Alzheimer’s diagnosis or predict the future of someone without cognitive complaints. FDA-cleared indications concern particular groups, including adults aged 55 or over with symptoms or concerns about cognitive decline. Physicians must interpret findings alongside clinical information, weigh false-positive and false-negative results, and discuss what the patient actually wants to know.















